← Back to Analyst Consensus 
VNDA Buy
Vanda Pharmaceuticals Inc.
Current Price —
Implied Upside —
Analysts 11
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Oct 28, 2026 (2 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Sep 23, 2026 | Oppenheimer | initiate | — → Outperform | — | 52% |
| Aug 10, 2026 | B. Riley Securities | reiterate | Buy → Buy | — | 54% |
| Aug 10, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| May 11, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 5, 2026 | Truist Securities | initiate | — → Buy | — | 54% |
| Feb 23, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $24 | 44% |
| Jan 5, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $22 | 44% |
| Dec 31, 2025 | B. Riley Securities | maintain | Buy → Buy | $14 | 54% |
| Dec 31, 2025 | Jefferies | maintain | Hold → Hold | $7.5 | 52% |
| Nov 19, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Nov 5, 2025 | B. Riley Securities | initiate | — → Buy | $11 | 54% |
| Oct 30, 2025 | Cantor Fitzgerald | maintain | Overweight → Overweight | $11 | 50% |
| Aug 21, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| May 7, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Apr 1, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Feb 18, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $20 | 44% |
| Feb 4, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $18 | 44% |
| Jan 28, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $18 | 44% |
| Jan 21, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $18 | 44% |
| Dec 23, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $18 | 44% |
| Oct 31, 2024 | HC Wainwright & Co. | initiate | — → Buy | $18 | 44% |
| Aug 1, 2024 | Cantor Fitzgerald | maintain | Overweight → Overweight | $13 | 50% |
| Jul 11, 2024 | Cantor Fitzgerald | initiate | — → Overweight | $11 | 50% |
| Feb 25, 2022 | Jefferies | downgrade | Buy → Hold | $12 | 52% |
| May 12, 2021 | B of A Securities | initiate | — → Buy | $22 | 53% |
| Jan 14, 2021 | Citigroup | downgrade | Buy → Neutral | $14 | 54% |
| Oct 29, 2020 | Citigroup | upgrade | Neutral → Buy | $14 | 54% |
| Jun 9, 2020 | Citigroup | downgrade | Buy → Neutral | $14 | 54% |
| Mar 12, 2020 | Citigroup | upgrade | Neutral → Buy | $14 | 54% |
| Feb 26, 2020 | Stifel | maintain | — → Hold | $13 | 53% |
| Feb 26, 2020 | JMP Securities | maintain | — → Market Outperform | $25 | 53% |
| Aug 1, 2019 | Citigroup | upgrade | Neutral → Buy | $19 | 54% |
| Jul 25, 2019 | Stifel | downgrade | Buy → Hold | $17 | 53% |
| Feb 6, 2019 | Cantor Fitzgerald | downgrade | Overweight → Neutral | $0 | 50% |
| Dec 11, 2018 | Stifel | maintain | Buy → Buy | $44 | 53% |
| Dec 11, 2018 | Oppenheimer | downgrade | Outperform → Perform | $29 | 52% |
| Dec 7, 2018 | Citigroup | maintain | Buy → Buy | $47 | 54% |
| Dec 6, 2018 | JMP Securities | maintain | Market Outperform → Market Outperform | $52 | 53% |
| Dec 4, 2018 | Cantor Fitzgerald | upgrade | Neutral → Overweight | $43 | 50% |
| Nov 8, 2018 | Jefferies | initiate | — → Buy | $26 | 52% |
| Oct 16, 2018 | Citigroup | maintain | Buy → Buy | $31 | 54% |
| Sep 21, 2018 | Oppenheimer | maintain | Outperform → Outperform | $29 | 52% |
| Sep 14, 2018 | Stifel | initiate | — → Buy | $30 | 53% |
| Aug 23, 2018 | Cantor Fitzgerald | initiate | — → Neutral | $26 | 50% |
| May 23, 2018 | Citigroup | initiate | — → Buy | $0 | 54% |
| Jan 19, 2018 | Seaport Global | initiate | — → Buy | $20 | 51% |
| Oct 30, 2017 | Oppenheimer | maintain | — → Outperform | $26 | 52% |
| May 26, 2017 | HC Wainwright & Co. | initiate | — → Buy | $18 | 44% |
| Apr 12, 2017 | Oppenheimer | initiate | — → Outperform | $0 | 52% |
Price Target Trend
Apr 26, 2026 Oct 26, 2026
EPS Estimates
+1q —
+1y —
0y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days